Buchumschlag

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Iskandar Idris
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Diabetes, Obesity and Metabolism Now
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
von: Iskandar Idris
Veröffentlicht: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
von: Iskandar Idris
Veröffentlicht: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
von: Iskandar Idris
Veröffentlicht: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
von: Iskandar Idris
Veröffentlicht: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
von: Iskandar Idris
Veröffentlicht: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
von: Iskandar Idris
Veröffentlicht: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
von: Iskandar Idris
Veröffentlicht: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
von: Iskandar Idris
Veröffentlicht: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
von: Iskandar Idris
Veröffentlicht: (2024)

Epigenetic changes shown to cause type 2 diabetes
von: Iskandar Idris
Veröffentlicht: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
von: Iskandar Idris
Veröffentlicht: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
von: Iskandar Idris
Veröffentlicht: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
von: Iskandar Idris
Veröffentlicht: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
von: Iskandar Idris
Veröffentlicht: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
von: Iskandar Idris
Veröffentlicht: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
von: Iskandar Idris
Veröffentlicht: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
von: Iskandar Idris
Veröffentlicht: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
von: Iskandar Idris
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
von: Suleiman Al Ashi, et al.
Veröffentlicht: (2025)

Metabolic dysfunction‐associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes
von: Chloë Aernouts, et al.
Veröffentlicht: (2024)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
von: Fu‐Shun Yen, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
von: Dario Giugliano, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
von: Claire H. Parker, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
von: Andy Bowe, et al.
Veröffentlicht: (2025)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
von: Iskandar Idris, et al.
Veröffentlicht: (2025)

Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009–2019
von: Naomi Holman, et al.
Veröffentlicht: (2025)

Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes
von: Ebaa Al Ozairi, et al.
Veröffentlicht: (2025)

Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
von: Claudio Maffeis, et al.
Veröffentlicht: (2024)

Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
von: Yu Peng, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
von: Lucas A. Mavromatis, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
von: Amanda R. Purcell, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
von: Frederick Berro Rivera, et al.
Veröffentlicht: (2024)